Karyopharm Therapeutics (KPTI) Receivables - Other (2016)
Karyopharm Therapeutics' (KPTI) quarterly Receivables - Other came in at $154000.0 in Q4 2016.
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) Receivables - Other (2016) Analysis & Trends
Karyopharm Therapeutics (KPTI) has reported Receivables - Other for 1 consecutive years, with $154000.0 the latest figure, recorded in Q4 2016.
- For the quarter ending Q4 2016, Receivables - Other changed N/A year-over-year to $154000.0; the trailing twelve-month figure through Dec 2016 stood at $154000.0 (changed N/A YoY), and the FY2016 full-year result was $154000.0, changed N/A from the prior year.
- Receivables - Other steadied at $154000.0 in Q4 2016 per KPTI's latest filing.
- Across five years, Receivables - Other topped out at $154000.0 in Q4 2016 and bottomed at $154000.0 in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 446.62 Bn | 440.05 Bn | 12.70 Bn |
| 3 | Merck | 358.24 Bn | 351.10 Bn | 12.21 Bn |
| 4 | Novartis Ag | 268.40 Bn | 260.71 Bn | 11.24 Bn |
| 5 | Pfizer | 157.04 Bn | 145.34 Bn | 10.94 Bn |
| 6 | Sanofi | 52.18 Bn | 44.80 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.98 Bn | 42.98 Bn | - |
| 8 | Incyte | 24.83 Bn | 20.30 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.38 Bn | 18.72 Bn | 683.80 Mn |
| 10 | Karyopharm Therapeutics | 46.73 Mn | -18.37 Mn | 32.35 Mn |